{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:47:13Z","timestamp":1776185233642,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008867","name":"Department of Education of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008867","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013314","name":"Higher Education Discipline Innovation Project","doi-asserted-by":"publisher","award":["D16013"],"award-info":[{"award-number":["D16013"]}],"id":[{"id":"10.13039\/501100013314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020346","name":"Ningbo University Li Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020346","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004387","name":"Ningbo University","doi-asserted-by":"publisher","award":["2026-2"],"award-info":[{"award-number":["2026-2"]}],"id":[{"id":"10.13039\/501100004387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejmech.2026.118799","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T18:03:28Z","timestamp":1774461808000},"page":"118799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design and synthesis of novel 1,2,4-triazolobenzene sulfonamide derivatives as selective CDK1 inhibitors with potent in vivo anticancer efficacy"],"prefix":"10.1016","volume":"310","author":[{"given":"Lingjie","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaojie","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aili","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4371-4746","authenticated-orcid":false,"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118799_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2024.100030","article-title":"Cell cycle dysregulation in cancer","volume":"77","author":"Glaviano","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2026.118799_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118799_bib3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: the road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118799_bib4","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.3390\/cancers14112658","article-title":"An integrative human pan-cancer analysis of cyclin-dependent kinase 1 (CDK1)","volume":"14","author":"Liu","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.118799_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41698-023-00407-7","article-title":"Targeting CDK1 in cancer: mechanisms and implications","volume":"7","author":"Wang","year":"2023","journal-title":"NPJ Precis. Oncolo."},{"key":"10.1016\/j.ejmech.2026.118799_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.118799_bib7","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1158\/1078-0432.CCR-14-0816","article-title":"Molecular pathways: targeting the cyclin D-CDK4\/6 axis for cancer treatment","volume":"21","author":"VanArsdale","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118799_bib8","doi-asserted-by":"crossref","first-page":"8488","DOI":"10.3390\/ijms24108488","article-title":"Abemaciclib, palbociclib, and ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer","volume":"24","author":"Cejuela","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118799_bib9","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","article-title":"Mechanisms of sensitivity and resistance to CDK4\/6 inhibition","volume":"37","author":"\u00c1lvarez-Fern\u00e1ndez","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118799_bib10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3390\/cancers18020329","article-title":"Frontiers in cell-cycle-targeting therapies: addressing the heterogeneity of the cancer cell cycle","volume":"18","author":"Ganesan","year":"2026","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.118799_bib11","first-page":"3263","article-title":"Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells","volume":"63","author":"Raju","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118799_bib12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.semcancer.2022.12.006","article-title":"CDK inhibitors from past to present: a new wave of cancer therapy","volume":"88","author":"Mughal","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2026.118799_bib13","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2011-12-400184","article-title":"ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol","volume":"120","author":"Mahoney","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118799_bib14","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/leu.2012.144","article-title":"The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells","volume":"26","author":"Johnson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2026.118799_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116547","article-title":"Targeting cyclin-dependent kinases: from pocket specificity to drug selectivity","volume":"275","author":"Huang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118799_bib16","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1021\/jm050267e","article-title":"1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities","volume":"48","author":"Lin","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118799_bib17","doi-asserted-by":"crossref","first-page":"9038","DOI":"10.1158\/0008-5472.CAN-05-0882","article-title":"The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases","volume":"65","author":"Emanuel","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118799_bib18","first-page":"39873","article-title":"Discovery of potential inhibitors of CDK1 by integrating pharmacophore-based virtual screening, molecular docking, molecular dynamics simulation studies, and evaluation of their inhibitory activity","volume":"9","author":"Teotia","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.118799_bib19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41388-022-02572-8","article-title":"The CMG helicase and cancer: a tumor \u201cengine\u201d and weakness with missing mutations","volume":"42","author":"Xiang","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.118799_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11638","article-title":"Structure of human Cdc45 and implications for CMG helicase function","volume":"7","author":"Simon","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118799_bib21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12967-024-05038-5","article-title":"CDC45 promotes the stemness and metastasis in lung adenocarcinoma by affecting the cell cycle","volume":"22","author":"Liu","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.118799_bib22","article-title":"Unraveling the guardian: p53's multifaceted role in the DNA damage response and tumor treatment strategies","volume":"25","author":"Zhang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118799_bib23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13046-018-0705-7","article-title":"New therapeutic strategies to treat human cancers expressing mutant p53 proteins","volume":"37","author":"Blandino","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118799_bib24","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.3390\/ijms20246241","article-title":"Do mutations turn p53 into an oncogene?","volume":"20","author":"Pitolli","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118799_bib25","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1080\/15384101.2016.1152424","article-title":"Cdc45 is limiting for replication initiation in humans","volume":"15","author":"K\u00f6hler","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2026.118799_bib26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41388-022-02572-8","article-title":"The CMG helicase and cancer: a tumor \u201cengine\u201d and weakness with missing mutations","volume":"42","author":"Xiang","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.118799_bib27","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.3390\/ijms22115516","article-title":"8a, a new acridine antiproliferative and pro-apoptotic agent targeting HDAC1\/DNMT1","volume":"22","author":"Zhang","year":"2021","journal-title":"Int. J. Mol. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426002448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:47:06Z","timestamp":1776181626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426002448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"alternative-id":["S0223523426002448"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118799","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of novel 1,2,4-triazolobenzene sulfonamide derivatives as selective CDK1 inhibitors with potent in vivo anticancer efficacy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118799","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118799"}}